Tawhari Mohammed, Alrushid Eythar, Alquwaiee Ghadah, Alanazi Shuq, Alkhudair Joud, Aldalaan Abdulaziz, Alsuwaid Shikah, Alabdulkarim Aljawharah, Tawhari Fawaz, Hattan Khaled M, Tawhari Ibrahim, Radwi Mansoor
Nephrology, King Abdulaziz Medical City Riyadh, Riyadh, SAU.
Nephrology, King Abdullah International Medical Research Center, Riyadh, SAU.
Cureus. 2022 Mar 28;14(3):e23575. doi: 10.7759/cureus.23575. eCollection 2022 Mar.
Background Patients with end-stage kidney disease (ESKD) are disproportionately vulnerable to COVID-19 and its complications due to the older age and significant burden of comorbid conditions. Data about the impact of COVID-19 on the ESKD population in the Kingdom of Saudi Arabia is scarce, and this study aims to bridge this gap. Method This is a retrospective cohort study that included ESKD patients who were receiving either in-center hemodialysis (HD) or peritoneal dialysis (PD) for at least three months and were hospitalized due to COVID-19 at King Abdulaziz Medical City in Riyadh (KAMC) between March 2020 and March 2021. Of note, the in-center hemodialysis means that the patients come to the dialysis center three times per week to receive their dialysis sessions, as home hemodialysis is not available at our center. Multivariate logistic regression was performed to explore the association of clinical characteristics and laboratory parameters with ICU admission and mortality. Results A total of 104 patients were included in the analysis. The mean age was 62.6 (SD=17.4) years, 101 (97%) were on HD, predominantly through a central venous catheter (72%), and 53 patients (51%) were male. Patients with COVID-19 were either asymptomatic (42%) or had mild symptoms (37%), mainly cough and fever. At the time of admission, 37 patients (36%) had extrapulmonary symptoms, and 13 patients (12%) had altered mental status. Normal chest X-ray (48%), followed by bilateral lung infiltrates (24%), and unilateral lung infiltrate (11%) were the most common radiological findings. We did not observe any thromboembolic events. Twenty patients (19%) required ICU admission and 19 patients (18%) died during hospitalization. Predictors for in-hospital mortality were: 1) the need for inotropes (adjusted OR: 53.01, p=0.006), 2) age (adjusted OR: 1.07, p=0.019), and 3) C-reactive protein (CRP) level on admission (adjusted OR: 1.02, p=0.04). We did not find any strong predictor for ICU admission. Conclusion Our study demonstrated that COVID-19 carries significant mortality and morbidity in the ESKD population. Age, inotropic support requirement and elevated CRP on admission predicted mortality in our population. The high rate of adverse outcomes of COVID-19 among ESRD patients calls for strict implementation of preventive measures, including vaccination, social distancing, and universal masking at the level of both the healthcare providers and patients. Further studies are needed to assess the association of COVID-19 and hypercoagulability ESKD population.
终末期肾病(ESKD)患者因年龄较大和合并症负担较重,更容易受到新冠病毒(COVID-19)及其并发症的影响。关于COVID-19对沙特阿拉伯王国ESKD人群影响的数据很少,本研究旨在填补这一空白。方法:这是一项回顾性队列研究,纳入了在利雅得阿卜杜勒阿齐兹国王医疗城(KAMC)接受中心血液透析(HD)或腹膜透析(PD)至少三个月且因COVID-19于2020年3月至2021年3月住院的ESKD患者。需要注意的是,中心血液透析是指患者每周到透析中心三次接受透析治疗,因为我们中心没有家庭血液透析服务。采用多因素逻辑回归分析探讨临床特征和实验室参数与入住重症监护病房(ICU)及死亡率的相关性。结果:共有104例患者纳入分析。平均年龄为62.6(标准差=17.4)岁,101例(97%)接受HD治疗,主要通过中心静脉导管(72%),53例患者(51%)为男性。COVID-19患者要么无症状(42%),要么症状轻微(37%),主要症状为咳嗽和发热。入院时,37例患者(36%)有肺外症状,13例患者(12%)有精神状态改变。胸部X线正常(48%),其次是双侧肺部浸润(24%)和单侧肺部浸润(11%)是最常见的影像学表现。我们未观察到任何血栓栓塞事件。20例患者(19%)需要入住ICU,19例患者(18%)在住院期间死亡。住院死亡率的预测因素为:1)需要使用血管活性药物(调整后的比值比:53.01,p=0.006),2)年龄(调整后的比值比:1.07,p=0.019),3)入院时C反应蛋白(CRP)水平(调整后的比值比:1.02,p=0.04)。我们未发现任何强烈的入住ICU预测因素。结论:我们的研究表明,COVID-19在ESKD人群中导致了显著的死亡率和发病率。年龄、血管活性药物支持需求以及入院时CRP升高是我们人群死亡率的预测因素。ESRD患者中COVID-19不良结局的高发生率要求严格实施预防措施,包括医疗服务提供者和患者层面的疫苗接种、社交距离和普遍佩戴口罩。需要进一步研究评估COVID-19与ESKD人群高凝状态的相关性。